This finding was indicative of the directly contrasting results for rates of major adverse cardiac events at @-year follow up ( zotarolimus @/@ -LSB- @ % -RSB- vs sirolimus @/@ -LSB- @ % -RSB- ; OR @ , @ % CI @-@ @ ; p < @ ) compared with those at follow-up between @ and @ years ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ; OR @ , @ % CI @-@ @ ; p = @ ) .